In a recent transaction, Norry Elliot, the Chief Medical (TASE:) Officer of Adaptimmune Therapeutics PLC (NASDAQ:), executed a sale of 5,584 American Depositary Shares (ADS) on January 17, 2025. The shares were sold at a weighted average price of $0.5808 per share, generating a total of approximately $3,243. According to InvestingPro analysis, ADAP is currently trading below its Fair Value, with the stock down over 50% in the past six months despite maintaining strong liquidity ratios.
Each ADS represents six ordinary shares of the company. The sale was part of a “Sell to Cover” exercise, which was automatically implemented to meet tax withholding obligations and associated costs. Following this transaction, Elliot retains ownership of 7,510 ADSs. InvestingPro subscribers can access 10 additional key insights about ADAP, including detailed financial health metrics and comprehensive valuation analysis in the Pro Research Report,…
